Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
BACKGROUND:
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes
Management of myelodysplastic syndromes after failure of response to hypomethylating agents
Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor prognosis and limited therapeutic options. Identification of patients who will respond to HMAs is challenging. Mechanisms underlying resistance to HMAs are not clear yet.
The case for upfront HLA-matched unrelated donor HCT as a curative option for adult acquired severe aplastic anemia: Upfront MUD HCT for adult severe aplastic anemia
Improved success of HLA-matched unrelated donor (MUD) hematopoietic stem cell transplantation (HCT) for severe
35th Anniversary Podcast Series: Stephen King, Aplastic Anemia and PNH
Stephen King, patient and Board Member for AAMDSIF
35th Anniversary Podcast Series: Mary and Courtney White, family of Aplastic Anemia
Mary and Courtney White, spouse and daughter of patient, volunteers for AAMDSIF
35th Anniversary Podcast Series: Dr. Inga Hofmann-Zhang
Dr. Inga Hofmann is a University of Wisconsin Health pediatrician who specializes and is director of pediatric bone marrow transplant and hematology. She is devoted to rare childhood bone failure diseases and myelodysplastic syndromes in her focus and Dr. Hofmann was recently appointed medical director of the PACT program for advanced cell therapy initiative, which is being led by Dr. Jacques Galippo, MD in the Department of Medicine. Dr Hofmann's role with PACT will facilitate an important collaboration between the new GMP lab and pediatric bone marrow transplant program.